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The present paper deals with the applicability of biological monitoring to the assessment of exposure and possible effects deriving
from exposure to engineered nanomaterials (NM). After establishing a conceptual framework in which human biomonitoring
should be placed, the paper reviews the critical issues related to the unusual properties of NM affecting the implementation of
biomonitoring activities for this new class of chemicals. Relying on the recent advances in the toxicogenomic, it is possible to
assess whether specific biological pathways are activated or perturbed by specific NM. However, to evaluate if quantitative changes
in these biomarkers can be used as indicators or predictors for toxicity in humans, validation on well characterised groups of
exposed people is needed. At present, it appears more pragmatic to evolve NM-associated biomarker identification considering
relevant biological responses found in environmental and occupational studies and assessing the early events associated with
exposure to these NM. The battery of biochemical markers includes soluble molecules, antioxidant capacity, peroxidated lipids and
carbonyl groups in serum proteins as a biomarkers of systemic inflammation and vascular adhesion molecules to assess endothelial
activation/damage. Abnormalities in exhaled breath condensate chemistry reflecting intrinsic changes in the airway lining fluid and
lung inflammation seem promising tools suitable for BM studies and are broadly discussed.
1. Definition and Meaning of Human
Biological Monitoring
Biological monitoring (BM) has been defined in different
ways, according to the purpose and the context [1–6].
In occupational health, BM deals with the systematic or
repetitive measurement of chemical or biochemical markers
in fluids, tissues, or other accessible samples from people
exposed to or with past exposure to chemicals risk factors.
The main objectives of such periodical measurements are (a)
the assessment of individual or group exposure; (b) ensuring
health protection by identifying early, specific nonadverse
biological effect parameters which are indicative, if compared
with adequate reference values, of an actual or potential
condition leading to health damage; ultimately (c) the
assessment of health risk to exposed subjects [2, 3]. BM can
be used as a valid tool in the practice of occupational safety
and health with the purpose of identifying potential hazards
of new and emerging chemicals, including manufactured
nanoparticles, and thus identifying groups at higher risk of
health outcomes [2].
BM is becoming more popular as the number of
biomarkers increases and the number of successful examples
of field application proves the validity of such biomarkers.
Biomarkers are regarded as early, preferably reversible, bio-
logical signs which are indicative, if compared with adequate
reference values, of an actual or potential condition of
exposure, effect, or susceptibility possibly resulting in health
damage or disease [3]. Biomarkers are increasingly used
as surrogate indicators of designated events in a biological
system due to the inaccessibility of target organs; in spite
of this limitation, it is thought that biomarkers are more
directly related to the adverse effects which one attempts
to prevent than any ambient measurement [4]. Depending
on their toxicological significance, biomarkers have been
classified in three main categories: biomarkers of exposure,
biomarkers of effect, and biomarkers of susceptibility. A
biomarker of exposure has been defined as “an exogenous
substance or its metabolite or the product of an interaction
between a xenobiotic agent and some target molecule or cell
that is measured in a compartment within an organism”
[5]. Providing objective demonstration of the absorption of
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chemicals in the body, exposure biomarkers can be useful in
occupational toxicology for a more accurate risk assessment,
reducing misclassification in epidemiological studies, and
modelling internal dose.
A biomarker of effect is “any measurable biochemical,
physiological or other alteration within an organism that,
depending onmagnitude, can be recognized as an established
or potential health impairment or disease” [5]. Biomarkers
of effect can be used in health surveillance programs aimed
at the early diagnosis of exposure-related (or associated)
diseases, but the application of effect monitoring is most
often used to evaluate whether a well-characterized exposure
is associated with a shift in the distribution of relevant
biochemical or functional endpoints indicative of early
changes in the target or critical organs/tissue. Biomarkers
of susceptibility, including both inherent (e.g., genetic poly-
morphisms of toxicologically relevant phenotypes of drug
metabolizing enzymes or DNA repair enzymes) and acquired
conditions [5], should help to distinguish groups at risk at
the same exposure levels, but they should be used as effect
modifiers rather than as risk factors.
For preventive purpose, biomarkers should not be con-
sidered as diagnostic tests but rather as indicators reflect-
ing early modifications preceding progressive structural or
functional damage at the molecular, cellular, and tissue
level, that is, changes possibly leading to adverse effects but
completely reversible upon the removal from the exposure of
concern. In order to be useful in risk assessment, a biomarker
should provide relevant information on important issues
concerning health risks and valid from both analytical and
epidemiological aspects [6]. Validity relies on the intrinsic
characteristics of the biomarker, due to its pathophysio-
logical meaning, that is, the ability to reflect, even subtle,
changes in a biological system; in particular, external validity
is required to obtain results which can be generalized to other
populations [2].
2. Critical Issues of Biomonitoring for
Engineered Nanomaterials
The development of appropriate biomarkers requires the
knowledge of pharmacokinetic and pharmacodynamic data
for a given chemical, which are still lacking for many classes
of NMs, in spite of the great development of in silico models
[7]. The internal dose of a given chemical is usually assessed
by both the amount of the chemical and/or its metabolites
and the products of interaction with target biomolecules
(DNA, proteins). For some metal nanoparticles, fullerenes
and Single-Wall Carbon Nanotubes (SWCNTs), the available
biokinetic data [8, 9] reveal appreciable translocation rates
from the lung interstitium to bloodstream and secondary
organ. Although such mechanisms can potentially explain
the manifestations attributable to UFP exposure, at present,
it is unknown whether it could represent a causal pathway for
NM entailing nano-specific outcomes.
As compared to other chemical substances, NMs do
not undergo biotransformation leading to moieties, or
break, down by, products; on the other hand, the particle
opsonisation by serum or membrane proteins, the specific
proteins coating the nanoparticle surface (“corona” effect), is
one of the key factors determining the fate and outcomes of
nanomaterial interacting with biological systems [10, 11].
A specific type of interaction occurs when proteins
adsorb, and this interaction affects both the particle and
the protein function. For instance, 14 nm carbon black
(CB) significantly adsorbs the cytokines IL-8 and TNF-alpha
compared with a similar dose of 260 nm CB [12]. TNF alpha
bound to 14 nm CB induced a level of ICAM-1 expression
that was no greater than the control level, suggesting that the
TNF alpha activity may be inhibited.
Metal nanoparticles like cobalt [13], iron oxide [14] and
zinc oxide, silver [15] can release metal ions, and the role
of particle dissolution in biological media, as well as its
prevention by doping particle surface, has paid attention
for the clearance of the particle out of the deposition
sites and for the effects of particles in target organs [8,
14, 16]. Agglomeration and solubility largely affect the
biological behaviour of NMs and, ultimately, their organ
distribution; low-soluble CNT or TiO2 nanoparticles show
biopersistence, and their slow clearance lead to the tendency
to accumulate over time with exposure [8, 9]. Although some
NMs have demonstrated to easily cross biological barriers,
the magnitude of NMs into the systemic circulation could
be negligible to lead significant internal dose. Analytical
capabilities now permit quantization of “background levels”
in people not knowingly exposed, but the toxicological
significance of these low doses needs to be carefully assessed
[17].
Data generated by toxicological tests can be used to
establish a quantitative relationship between the different
physico-chemical characteristics of nanoparticles and the
response elicited [18]. For nanoparticles, controversies exist
about the best descriptor of dose related with biological
effects, particle number, and surface area being the best dose
metrics for NMs both in vitro and in vivo. [19–21]. The
unpredictable behaviour of several NMs would require to
assess the dose-response relationship of the most sensitive
body organ rather than solely on the organ through which
nanoparticles enter the body. Although understanding target
organ dose is still problematic, new methods for tracking
and measuring NMs in vivo, currently applied to assess the
effectiveness of dose delivered at target cells [22, 23], could
provide effective tools for obtaining quantitative data that
are essential for dosimetry model validation and, ultimately,
for ascertaining the range of exposure level with no observed
adverse effects (NOAELs).
3. Identifying Relevant Effects and Mechanisms
To develop biomarkers suitable for human studies involving
people exposed to NMs, it has been suggested to use a step-
wise approach to evolve nanoparticle-associated biomarker
identification from biochemical, cellular, and animal stud-
ies, the same approach that has been used for studying
air pollution-associated biomarkers [24]. Inhaled ultrafine
particles (UFPs) and combustion-derived nanoparticles are
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capable of inducing oxidative stress in the lung as well as
in systemic circulation and are involved in many adverse
effects or pathological conditions associated with respiratory
and cardiovascular disease outcomes. For environmental
particles, oxidative stress and changes to biomolecules may
arise from direct generation of reactive oxygen species from
the surface, soluble compounds, such as, transition metals
or organics, altered function of mitochondria or NADPH-
oxidase, and activation of inflammatory cells capable of
generating ROS and reactive nitrogen species [25].
It should be emphasized that incidental UFPs, mostly
generated by combustion sources, are heterogeneous in size
and composition (including organics undergoing metabolic
activation and producing reactive species, such as, polynu-
clear aromatic hydrocarbons, elemental carbon and metals),
whereas NMs are intentionally made of defined composition
and surface chemistry. Although similar in size, ambient and
engineered nanoparticles may significantly differ for bio-
logical activity and toxicological properties. Since ambient
UFPs are one of the components of a complex mixture of
pollutants including oxidant gases and biocontaminants, it
is difficult to attribute specific health outcomes to a specific
class of contaminants.
Recent research has identified the most significant bio-
logical responses and target organ affected by different NM
[18, 26–28] and the toxicity paradigms have been elucidated
[15, 29, 30].
Figure 1 summarizes some potential important factors in
correlating exposure, dosimetry, and health effects of inhaled
nanoparticles. Since nanoparticles have a greater potential to
deposit and target both the upper and lower regions of the
respiratory system and are capable to induce more oxidative
stress and inflammation than their fine-sized counterparts,
possibly leading to long-term effects, this justifies the study
on their health impact [28].
Epidemiological studies have found hazardous respira-
tory effects from occupational exposure to some industrial
processes involving generation of significant amounts of
UFP, such as, carbon black [31], fumed silica [32], and
metal oxide [33, 34]. However, also some few NMs, such
as, titanium dioxide (TiO2), copper oxide (CuO), ZnO
and iron oxide nanoparticles, cationic polystyrene, and
C60 fullerene have demonstrated to have prooxidative and
proinflammatory properties both in vitro and in vivo, mainly
related to their surface reactivity and chemical composi-
tion [28], although not all NPs cause inflammation via a
mechanism involving oxidative stress. Experimental studies
have characterized tissue response to carbon nanotubes
(CNTs) and showed that deposition following instillation
or inhalation leads to transient inflammatory changes, lung
tissue remodelling, and fibrosis [35, 36].
Since NMs can potentially affect multiple cellular func-
tions and interfere with many components of the cell
machinery [37], it is difficult to determine with conventional
assay what are changes and adverse effects that may occur,
and whether biochemical and/or functional changes can be
material-specific or exposure-route specific. Conventional
toxicology has used surrogate markers that are correlated
with toxic responses to monitor adverse outcomes in inacces-
sible tissues. An alternative approach is suggested by system
toxicology, which postulates that there are size-specific,
shape-specific, and surface-specific effects and effectors for
particles at the quantum range, which are different from the
effects observed for microsized particulates [37–39].
The process of determining the relationship between a
particular expression profile and the toxicological phenotype
of the organism for a particular exposure or dose and at
a particular time is called “phenotypic anchoring”. This
approach can be used in conjunction with lower doses of
the toxicant to classify agents and to explore the mechanisms
of toxicity, for example, by assessing transcriptional changes
occurring after exposure to both low- and high-dose of
NMs, and detecting the biological responses by using
transcriptome measurements. Toxicogenomics approach has
been used in assessing specific mechanisms at the molecular
level for silicon dioxide, dendrimers, and carbon nanopar-
ticles, for example, SWCNT, Multi-Wall carbon Nanotubes
(MWCNTs), carbon nanoonions and fullerenes, and metal
nanoparticles (e.g., copper and silver), identifying patterns of
cellular perturbations in specific pathways, through identifi-
cation and quantification of global shifts in gene expression
in cell models challenged with NMs [38–42].
SWCNT may induce cell apoptosis, which is charac-
terized by upregulation expression of apoptosis-associated
genes (e.g., p16, bax, hrk, bak1, p57, FGFR2,TGF beta receptor
1 and TNFAIP2 genes) and downregulation expression of
cell-cycle-associated genes (such as cyclin D1, cdk2, cdk4, and
cdk6) as compared to normal cells [40]. Silica nanoparticles
induced a higher level of acute phase proteins, such as,
haptoglobin, C-reactive protein (CRP), and serum amyloid
A (SAA) than larger silica particles (diameter >100 nm)
after intravenously treatment; acute phase proteins, such as
haptoglobin were significantly elevated in plasma of mice
exposed to silica nanoparticles with a diameter of 70 nm
(nSP70) compared to normal mice and those exposed to
silica particles with a diameter of 1000 nm. Furthermore, the
CRP and SAA were also elevated in plasma of nSP70-treated
mice. In addition, the level of these acute phase proteins was
elevated in the plasma of mice after intranasal treatment with
nSP30 [42].
Whole genome microarray analysis of the early gene
expression changes induced by 10 and 500 nm amorphous
silica nanoparticles showed that the magnitude of change for
the majority of genes affected correlated more tightly with
particle surface area than either particle mass or number,
and gene expression changes were particle size specific [41].
However, the overall biological processes represented by all
gene expression changes were nearly identical, irrespective of
particle diameter, suggesting that on an equivalent nominal
surface area basis, common biological modes of action are
expected for nano- and supranano-sized silica particles.
The most robust transcriptional change observed was an
induction of the Cxcl2 chemokine (MIP-2a), also implicated
in crystalline silica-induced lung neutrophil recruitment
[41].
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Figure 1: Potential important factors in correlating exposure, internal dose, and health effects of nanoparticles.
Pulmonary exposure to CNT resulted in an elevated
series of measurable potential biomarkers in blood, includ-
ing, genes expressed in the circulating blood cells and/or
soluble proteins not unique to the type of particles [43].
In particular, MWCNT induced gene upregulation of more
than half of the tested genes in the lung related to inflam-
mation, oxidative stress, coagulation, and tissue remodelling
and in a significant increase in the circulating blood gene
expression of several biomarkers of neutrophil response.
Interestingly, several genes were activated in the circulating
blood cells but not in the lung at least at the 4 h after
pulmonary exposure to MWCNT, for example, osteopontin,
colony stimulating factor-1 (CSF-1), and insulin growth
factor receptor 1 (IGF-1R). Pulmonary exposure to CNT
also triggered the induction of primary cytokines, such as
IL-6 and IL-1β, which regulate multiple pathways of the
inflammatory cascade as well as secondary inflammatory
mediators and chemokines which directly regulate leukocyte
recruitment to the inflammatory site (32). Teeguarden et al.
[44] identified a pattern of 109 proteins representing cellular
processes affected by both SWCNT and crocidolite asbestos;
in particular, one high-sensitivity marker of inflammation
(S100a9) may represent a promising biomarker of human
response to SWCNT exposure.
High-throughput toxicological studies thus support the
existence of both nanoscale effects and specific molecular
effectors differentiating nanotoxicology from conventional
toxicology. Figure 2 summarizes such system-toxicology-
based integrative approach to the identification of biomark-
ers. The perspective of identifing fingerprints of selected
NMs by “-omic” techniques (i.e., metabolomic analy-
sis, toxicogenomic, oxidative lipidomics based on mass
spectrometry-based profiling of lipid profiles of exposed
cells and tissues) applied to nanotoxicology will allow to
assess whether particular biological pathways are activated
or perturbed by specific nanoparticles and to evaluate if
the quantitative changes in these biomarkers can be used as
indicators or predictors for toxicity in humans.
4. Biomarkers of Lung and
Systemic Inflammation
To assess the early events preceding progressive structural
or functional damage at the molecular, cellular, and tissue
level associated with exposure to NMs, the choice of
potential biomarkers to be studied can include the changes
that indicate local and systemic oxidative stress, systemic
inflammation, and inflammatory response in target organs,
such as, those in respiratory and cardiovascular systems.
Although inflammatory pathways are the main mechanism
investigated in relation to cardiovascular outcomes, other
mechanisms triggered by UFPs exposure, such as, the
involvement of vagal bronchopulmonary receptors and neu-
ronal pathways initiated in the lung, should be considered
[45].
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Figure 2: System toxicology-based integrative approach to the identification of biomarkers. Recent advances in “-omics” and new imaging
techniques describing the cellular fate of NMs may lead to identify fingerprints of selected NMs, to assess whether particular biological
pathways are activated or perturbed by NMs, and to evaluate if the quantitative changes in these biomarkers can be used as indicators or
predictors for toxicity in humans.
Quantification of lung inflamma tion is currently based
on invasive methods, including, the analysis of bronchoalve-
olar lavage fluid (BALF), bronchoscopy and bronchial
biopsies, semi-invasive methods, such as, sputum induc-
tion, and the measurement of inflammatory biomarkers
in plasma and urine which are likely to reflect systemic
rather than lung inflammation [46]. Breath analysis has
been suggested as a promising noninvasive approach that
allows the identification of the inflammatory and oxidative
stress biomarkers involved in the pathogenesis of various
respiratory conditions both for clinical applications [46] and
for investigating occupational lung diseases [47, 48].
Different biomarkers of effect, reflecting oxidative stress
and inflammatory pathways, can be determined in EBC
[46]; for instance, Thiobarbituric Acid Reactive Substances
(TBARSs), such as, malondialdehyde, produced by lipoper-
oxidation of membranes, and 8-isoprostane, a peroxidation
products of prostaglandin metabolism, can be quantified;
changes in pH, proteins, and proinflammatory cytokines,
such as, leukotrienes B4 (LTB4) can also be determined as
biomarkers of inflammation. Inflammatory response in the
airways is characterized by an influx of neutrophils, whose
activation is associated with a respiratory burst resulting
in overproduction of hydrogen peroxide (H2O2), which is
measurable in EBC. Glutathione (GSH), which is present
in high concentration in epithelial lining fluid and at tissue
level of the lung, represents one of the major biological
antioxidant defence mechanisms against reactive oxygen
species and the secondary products ROS reacting with thiol
groups can severely deplete the GSH pool.
Various classes of volatile organic compounds (VOCs)
can also be measured in exhaled breath, including, the
saturated hydrocarbons and oxygen-containing substances
formed during the fatty acid lipid peroxidation of cell
membranes [49].
A wide variety of carbonyl compounds are generated as
secondary oxidation products during respiratory burst. In
particular, saturated aldehydes, such as hexanal, heptanal,
and nonanal are formed by the peroxidation of omega-
3 and -6 fatty acids (PUFAs), the basic components of
cell membrane phospholipids. Volatile aldehydes are poorly
soluble in blood and are therefore excreted into the breath
within minutes of their formation in tissues, making it
possible for the study of pulmonary diseases associated with
inflammatory processes (e.g., COPD, asthma, interstitial
lung disease) and the early diagnosis of lung cancer [50, 51].
Nitric Oxide (NO) is produced by all cellular compo-
nents of pulmonary inflammation (macrophages, epithelial
cells, mast cells, lymphocytes, and granulocytes). Study-
ing NO exhaled from the lower airways offers a unique
possibility to study features of pulmonary NO metabolism
noninvasively in lung inflammatory states [52]. Under
physiologic conditions, NO is unstable, reacting with oxygen
to form oxides of nitrogen (NOx), such as, nitrite (NO2
−)
and nitrate (NO3
−) and with superoxide anion to form
the potent oxidant peroxynitrite (ONOO−), which reacts
with a wide variety of compounds, including, DNA, cellular
lipids, and sulphydryl groups on proteins thus promoting
nitrosative stress. Nitrosothiols (RS-NOs), which are formed
by interaction of nitric oxide (NO) with GSH, can be reliably
used as biomarkers in different inflammatory airway diseases
[53]. Nitrite and nitrate in EBC have been used in evaluating
the role of oxidative stress in acute responses to exposures
that occur inside vehicles or during near-roadway activities
[54].
A broad panel of circulating biomarkers reflecting
inflammation endpoint, platelet activation, and antioxidant
capacity by the copper-/zinc-superoxide dismutase (Cu,
Zn–SOD) and glutathione peroxidase-1 (GPx-1) activity
has been investigated in studies on air pollution and
health effects. Delfino et al. have assessed the relationship
between exposure to particles of 0.25 μm in aerodynamic
diameter (PM0.25), organic carbon, and elemental carbon
from outdoor sources and changes in circulating biomarkers
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of systemic inflammation [55, 56]. These studies showed
the inactivation of antioxidant enzymes within erythro-
cytes by traffic-related pollutant components, including,
polycyclic aromatic hydrocarbons, among a subgroup of
people. Plasma interleukin-6 (IL-6) and soluble tumor
necrosis factor-receptor II (sTNF-RII) were investigated
during a longitudinal study considering both indoor and
outdoor exposure and showed a positive association with
vehicle emissions tracer. High-sensitivity C-reactive protein
(hsCRP) in plasma, plasma fibrinogen, interleukin-6 (IL-6)
could represent the best candidate for human BM following
NM exposure.
Radomski et al. [57] showed that both urban dusts and
engineered carbon particles, such as, CNT and carbon black,
except C60CS, stimulated platelet aggregation and accelerated
the rate of vascular thrombosis in rat carotid arteries with
a similar rank order of efficacy. All particles resulted in
upregulation of GPIIb/IIIa in platelets. Similarly, exposure
to nano- Ag (0.05–0.1 mg/kg i.v. or 5–10mg/kg intratra-
cheal instillation) in vivo enhanced platelet aggregation and
promoted venous thrombus formation in rats [58]. Single-
walled carbon nanotubes (0.01–1mg/kg) were injected into
anesthetized mice, induced platelet activation in vitro, and
exerted prothrombotic effects in the microcirculation in vivo,
whereas similar dose of titanium dioxide (1mg/kg) did not
result in thrombus formation [59].
In order to assess early systemic prothrombotic effects
induced by fine particle (<2.5 μm) exposure, quantification
of tissue factor (TF) activity in plasma, which is expressed
in subendothelial cells upon injury or on the surface of
circulating monocytes, macrophages and neutrophils, and
the levels of plasminogen activator inhibitor-1 (PAI-1), can
also be proposed as biomarkers [60].
The endothelium plays an important role in maintaining
the vascular homeostasis by producing vasoactive factors that
regulate the tone of the vascular system in response to cell
surface receptor stimulation or mechanical stress but also
in the regulation of vascular inflammation and thrombosis.
NMs can directly affect endothelial cells metabolism via
oxidative stress generation and endothelial repair capacity
[61, 62]. For instance, exposure to ultrafine TiO2 particles
can affect vasomotor function with minimal pulmonary
effects [63]. Vesterdal et al. [64] showed that exposure of
young and aged apolipoprotein E knockout mice (apoE−/−)
to CB (Printex 90, 14 nm average size) by intratracheal
instillation, resulted in modest vasomotor impairment, with
a lack in association with nitrosative stress (3-nitrotyrosine)
and without increases in the expression of vascular adhesion
molecule (VCAM-1) and intercellular adhesion molecule
(ICAM-1) on endothelial cells or in plaque progression.
5. Biomarkers of Oxidative Stress and
DNA Damage
Panel studies and cross-sectional investigations on health
effects of particulate matter exposure have found consistent
associations between exposure to combustion-derived par-
ticles and products of oxidative damage of DNA and lipids
[65–67]. Among the DNA oxidation products, such as 8-
oxo-7,8-dihydroguanine (8-oxoGua) or the corresponding
deoxynucleoside 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-
oxodG) measured in DNA and urine, the exocyclic M1
adduct to guanine (M1dG) was the most studied. Among
the biomarkers of lipid peroxidation products measured in
EBC, blood, or urine, both conjugated dienes (CDs), lipid
hydroperoxides, malondialdehyde (MDA), Thiobarbituric
Acid Reactive Substances (TBARSs), and F2-isoprostanes
have been assessed. Base excision repair of oxidative dam-
age to DNA measured in urine, such as, 8-hydroxy-2′-
deoxyguanosine (8OHdG), seems to originate mostly from
the oxidation of the deoxynucleotide pool and does not
represent solely repairing/excretion of the oxidized DNA
guanine. Once produced, 8OHdG is very stable and is
not further metabolized in the systemic circulation. After
exposure to oxidants, the repair and final 8OHdG excretion
in urine is rapid, that is, within at least 24 hours [68].
Increased 8OHdG urinary levels within each shift and
between days have been shown in workers exposed to low
levels of respirable PM4 (range 25–71 μg/m3) [69].
Whereas the DNA damaging potential of many nanopar-
ticles is known, in vitro studies have demonstrated that NMs
of different composition (metal/metal-oxide nanoparticles,
silica, quantum dots, fullerenes, nanofibers) can alter DNA
structure by oxidative mechanisms but can also interfere by
mechanical hindrance with cellular and nuclear components,
like, microtubules of the mitotic spindle [70, 71].
The majority of the NM tested both in vitro and in
vivo, such as, metal nanoparticles [13, 72, 73] and both SW-
and MWCNT [36, 74, 75] are able to cause DNA strand
breaks or oxidative DNA lesions. Chromosome breakage and
chromosome loss, the main genotoxicity endpoints, can be
detected and quantified in target cells using the cytokinesis-
block micronucleus method (CBMN assay), originated from
acentric chromosome fragments or whole chromosomes
lagging behind during cell division, coupled with the
fluorescence in situ hybridization (FISH) analysis. DNA
damage in peripheral blood leukocytes can be quantified
by single cell gel electrophoresis (SCGE; Comet assay) a
simple and sensitive method for detecting DNA strand
breaks and alkali-labile sites, while oxidatively damagedDNA
can be analyzed using the enzyme formamidopyrimidine
glycosylase (FPG) and endonuclease III (endo III) which
detect, respectively, oxidized purines and pyrimidines [75].
Although interactions between the particles and the assay
cannot be totally excluded, the use of Comet assay in human-
biomonitoring studies could provide valuable information
for hazard identification of NMs [76]. Some studies showed
dose-effect and dose-response relationships between the
mass concentration of NM and the frequency of micronu-
cleated lymphocytes, with a threshold for the above effects
[72, 75].
DNA methylation, a major genomic mechanism of gene
expression control, can be affected by reactive oxygen species
(ROS), which are considered one of the main cellular stres-
sors generated by PM exposure [77] as well as by somemetals
[78]. Conditions associated with reduced global DNAmethy-
lation content have been shown to interact with ambient PM
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exposure to produce health-related outcomes. For instance,
gene expression and the associated epigenetic changes have
been demonstrated following exposure to metal-rich PM
with aerodynamic diameters <10 μm (PM10)in workers in an
electric furnace [79].
MicroRNAs (miRNAs) are highly conserved, noncoding
small RNAs that regulate the expression of broad gene
networks at the posttranscriptional level [80] demonstrating
that gold nanoparticles (AuNPs) altered the expression of
19 genes in human fetal lung fibroblasts, upregulating the
microRNA-155 (miR-155), and downregulating the PROS1
gene. Silencing of miR-155 established PROS1 as its possible
target gene. DNA methylation profiling analysis of the
PROS1 gene revealed no changes in the methylation status
of this gene in AuNP-treated fibroblasts, whereas chromatin
condensation and reorganization were observed in the
nucleus of fibroblasts exposed to AuNPs. These findings
provide further insights into the molecular mechanisms
underlying toxicity of AuNPs and their impact on epigenetic
processes.
6. Biomarkers of Neurotoxicity
Existing research has shown that several NMs, like, quantum
dots [81] and SWCNT [82] are capable of crossing the blood-
brain barrier (BBB), damage it, and enter the brain. TiO2
[83] and manganese oxide nanoparticles were capable of
translocating along the olfactory nerve pathway to the brain
after intranasal instillation exposure, accumulating in the
olfactory bulb, cortex, and cerebellum [84]. The deposition
in the brain of NMs such as, ferrous oxide [85] and CB [86]
can stimulate oxidative stress, inflammatory responses, and
pathological changes. The mechanisms of neuron injury are
diverse for a wide variety of materials used and NMs produce
different effects from environmental particles with potential
effects both on peripheral and central nervous systems
[87]. Adsorption and inhibition of acetylcholinesterase, a
key enzyme present in the brain, blood, and nervous
system, by SiO2, TiO2, Al2O3, Al, Cu, carbon-coated copper,
SWCNT and MWCNT suggest an interference of NMs with
neurochemical processes and a use of AChE as a potential
biomarker of neurotoxicity [88]. Dopaminergic neurons can
be specifically targeted in vitro by a broad spectrum of NM,
including Mn, Ag, or Cu nanoparticles [89]. In vivo studies
showed SiO2-NPs entered into the brain and especially
deposited in the striatum and induced oxidative damage and
inflammation in dopaminergic brain areas with subsequent
depletion of neuromediators [90].
Aerosolized welding fumes generated from two different
welding processes, gas metal arc-mild steel (GMA-MS; low
Mn, less water soluble), andmanual metal arc-hard surfacing
(MMA-HS; high Mn, more water-soluble) welding caused
persistent molecular alterations in dopaminergic targets of
treated animals [91]. To assess early effects from chemicals
targeting the dopaminergic systems a neurochemical and
neuroendocrine approach based on surrogate biomarkers
in peripheral media has been previously developed [92].
Neurotoxicity of Mn to dopaminergic systems, investigated
in male workers occupationally exposed to Mn oxides
containing fumes and metallurgic dusts, was revealed by
increase in serum PRL levels [93].
It is unlikely that acute high dose causes CNS effects
occur, whereas the long-term accumulation of low doses of
ENP cannot be excluded; thus, the possibility that chronic
exposures to NM can influence brain neurochemistry trig-
gering or aggravating pathological processes cannot be ruled
out [94].
7. Development of Biomarkers for Human
Studies and Health Impact Assessment
The health effects of nanoparticles are, to a large extent,
unknown, and currently there is no report of any definitive
human disease that is caused by NMs exposure. Specific
health end points on which future human studies should
be focused are a controversial issue; as a result, studies
on chronic effects with adequate latency are probably not
feasible in the near future. In contrast, initial epidemiological
studies (e.g., based on a cross-sectional design) could benefit
of biomarkers to detect possible effects.
Therefore, there is a need for the selection of candidate
biomarkers of early effects to be used in human studies.
The literature on short-term effect of air pollutants
and the available literature on NMs suggests identifying
multiple biomarkers, a biomarker profile, to assess both
effects at the “portal of entry” (e.g., inflammatory changes,
short-term respiratory changes, respiratory, eye or skin
irritation) and systemic effects (e.g., heart-rate variability,
platelet aggregation and prothrombotic changes, acute phase
proteins) [95]. Biochemical tests or functional parameters
to be assessed should be supported by consistent patho-
physiological mechanisms, considering that the health end
points ascribed to UFP, and possibly to NM, (cardiovascular,
pulmonary, inflammatory) are often unspecific, show high
prevalence in the general population, and share multiple
nonoccupational risk factors [96].
Table 1 summarizes a panel of biomarkers of exposure
and effect potentially available for human biomonitoring
studies aimed at assessing early (i.e., subclinical) effects and
health outcomes forerunners of disease endpoints. In bold
are listed the more promising biomarkers (e.g., validated in
human studies on people exposed to different ultrafine or
fine particulates or fractions of them).
Since “nano-specific” biomarkers (or “nano-specific”
effects) are difficult to demonstrate, practical considerations
suggest to focus on the sensitivity instead of the speci-
ficity of biomarkers, to assess the causality of exposure
conditions/scenarios and association with hazards (e.g., at
workplace) but also to identify and validate, among a panel of
already available biomarkers, the most suitable for BM stud-
ies in people exposed to NMs [97]. In spite of the advances
made to ensure a higher degree of workers protection,
epidemiological data specifically derived from nanoparticle-
exposed humans, which should allow to validate biomarkers,
are currently not available, owing to a number of issues,
including the short latency since the introduction of NM
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Table 1: Biomarkers of exposure and effect potentially available for human biomonitoring studies assessing exposure-effect relationships
between particulate matter/ultrafine particles and health effects. In bold are listed the more promising biomarkers (e.g., validated in human
studies on people exposed to different ultrafine or fine particulates or known fractions), whereas in italic are reported some potential
biomarkers. Legend: EBC: Exhaled Breath Condensate; MDA: Malondialdehyde; T-BARS: Thiobarbituric Acid Reactive Substances; LTB4:
Leucotriene-B4; NO: Nitric Oxide; 8-OH-dG: 8-hydroxy-2′-deoxyguanosine; 8-oxo-Gua: 8-oxo-7,8-dihydroguanine; 4-HNE: 4-hydroxy-2-
nonenal; CC16: Clara Cell protein; hsCRP: high sensitivity C-reactive protein; IL-6: plasma Interleukin 6; sTNF-RII: soluble Tumor Necrosis
Factor-receptor II; PAI-1: plasminogen activator inhibitor-1; V-CAM: vascular adhesion molecule; FPG-ENDOIII: lesions detected as sites
in DNA sensitive to formamidopyrimidine DNA glycosylase and endonuclease III.
Exposure Effective dose/early effect Altered structure/function
(i) Exhaled particles in EBC (“deposited dose”)
(i) Lipid peroxidation products in EBC or
blood (MDA, T-BARS, conjugated dienes,
LTB4, F2- and 8-isoprostane)
(i) Fibrogenic markers
(ii) Circulating particles
(ii) Oxidatively damaged DNA (8-OH-dG, 8-
oxo-Gua)
(ii) Cell transformation assays
(iii) Particle uptake by specialized cells (e.g.,
macrophages)
(iii) Exhaled NO and nitrosative stress products
(3-nitrotyrosine)
(iii) Micronucleus
(iv) Elemental analysis (for metallic NM, e.g.,
metal oxides) in biological fluids
(iv) Carbonyl compounds (4-HNE) in EBC
(iv) DNA strand breaks (Comet
assay + FPG-ENDO III)
(v) Protein modification (“corona”) (v) Serum pneumoproteins (CC16) (v) DNA hypomethylation
(vi) Platelet activation/aggregation and pro-
thrombotic changes
(vi) MicroRNAs (miRNAs)
(vii) Acute phase proteins (hsCRP), IL-6, and
sTNF-RII
(viii) Clotting factors (fibrinogen, PAI-1),
blood microparticles
(ix) Tissue factor (TF) activity in plasma
(x) Vascular adhesion molecules (V-CAM-1)
(xi) Upregulation of GPIIb/IIIa in platelets
on the market, the overlap in exposure to combustion-
derived UFP and engineered nanoparticles, the lack of
standardized exposure metrics, the difficulty in identifying a
target population with long, and consistent exposure leading
to appreciable health effects [98].
In epidemiological research, BM is aimed at overcoming
the growing frustration with the limitations of such crude
markers of exposure as job titles, exposure registries or point
estimates of airborne pollution. We should instead assess
whether exposure to different NMs may lead to the same
pathway for disease or share common mechanisms. But,
to avoid “epidemiological frustrations” it is mandatory to
identify at least intermediate biological changes of “acute” or
“short-term” effects that could be indicative, if not predictive,
of disease and apply them in cross-sectional investigations
combining both exposure characterization to a given NM
and sufficiently validated biomarkers.
For the NMs with known mechanisms or that share
similar injury mechanisms (i.e., oxidative stress and inflam-
mation, DNA damage) with UFPs, it is theoretically fea-
sible to conduct biomarker studies starting with similar
approaches; for example, to assess the early events associated
with exposure to these NPs, biochemical changes indicative
of local and systemic oxidative stress, systemic inflammation,
and inflammatory response in target organs can be used [99].
Inflammatory biomarkers could be monitored in workers by
using noninvasive methods (e.g., EBC collection). Pneumo-
proteins such as Clara cell protein (CC16) and surfactant-
associated protein B (SP-B) in the serum have been validated
as markers of alveolocapillary barrier integrity/permeability
in human studies on gaseous/particulate pollutants [100,
101]. Recently, CC16 determination in serum was studied in
workers occupationally exposed to NM [102]. Besides CC16,
the high-sensitivitiy Reactive C protein levels and inflam-
matory cell activation (increased ICAM-1 in macrophages)
showed statistically significant changes among NM workers.
To date, exposure assessment and characterization rep-
resent the main issues in risk assessment; provided that
exposure is, quantitatively or qualitatively, documented, then
BM studies could be consistently implemented. Metal NPs
which release metal ions or dissolve in biological media
may be detectable (as metal species, not as particles) with
appropriate analytical methods.
To give an estimate of deposited dose of particles by
noninvasive techniques, Goldoni et al. [103] have developed
a portable device designed to monitor the on-line exhalation
kinetics of particles in a single breath and validated it in
field studies of workers occupationally exposed to cristobalite
in the size range of 0.3–2.5μm [103] and to welding
fumes [104]. Although the advantages of such an approach
need further validation with different aerosols and model
nanoparticles, the method suggests a tool to assess the dose
of particles deposited within the respiratory tract.
By the breath analysis, tissue dose of pneumotoxic metals
has been assessed in both workers occupationally exposed to
hard metals (Co, Ti) [105], chromium(VI) [106]. Whether
this technique is applicable to quantify the dose of metals
eventually released by NMs deposited in the airways should
be further assessed in field studies.
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Although we are not able, at present, to identify “nano-
specific” biomarkers that meet all the above criteria, we can
use a battery of available biomarkers of local and systemic
inflammation and oxidative stress to identify hazards and
groups at risk. Certainly, it will take years to develop a panel
of biomarkers suitable as indicators of exposure-specific
disease outcomes, but relying on our knowledge from the
air pollution studies, occupational exposures to particles
and fibres of concerns, and advances in “-omics” techniques
applied to nanotoxicology we can identify early biological
responses related to injury pathways upon exposure to NMs.
Practical issues, including, cost, exposure levels (which
are able to lead to “effective dose”), analytical requirements,
and selection of an adequate sampling strategy, should
be considered in every study. Biological materials should
certainly be easy to obtain in sufficient amounts under
routine conditions and without unacceptable discomfort and
health risk for the individual or worker.
Evaluation of the possible health effects from expo-
sure to NMs requires a stepwise approach considering
the knowledge of the likelihood of a known exposure,
tracking changes of such characterized exposure over time
by exposure registries, conducting targeted epidemiological
investigations, and possibly applying selected biomarkers
[2, 24, 107, 108].
There are many efforts at international level to identify
companies manufacturing NM and workers likely to be
exposed to NMs, and some studies on occupational cohorts
have been put in place [108–110]. The heterogeneity of NMs,
making difficult to identify and recruit enough workers with
the same exposure pattern, could be addressed by the use of
biomarkers [98].
The feasibility of BM studies in NM workers should
consider both conceptual and practical issues, such as:
(i) data on the temporal trends in exposure levels; (ii)
identification of parameters able to reflect internal exposure
or early/reversible biological changes; (iii) specific analytical
methods kept under control by quality assurance; (iv)
establishing reference ranges and limit values which enable
the interpretation of eventual changes; (v) assessment of the
health significance and predictive value of observed changes.
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